"The Great Healthcare Plan" aims to lower drug costs, reduce premiums, and enhance price transparency, with a focus on Most ...

Despite HCM’s strong genetic basis, patients residing in lower-income or more socially deprived areas faced significantly ...

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

Standardized monitoring workflows and clearer reimbursement support are critical to improving community clinicians’ readiness ...

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of ...

Reducing liver fat has become a central target in the development of therapies for metabolic dysfunction–associated ...

ICHRAs have been growing in popularity, but not without skepticism. While some consumers think they are inferior to ...

Retrospective studies show elevated risks, especially for glomerular or proteinuric kidney disease, but absolute risk remains ...

Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and ...